Sarepta receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc stock price live, this page displays NASDAQ SRPT stock exchange data. View the SRPT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Sarepta Therapeutics Inc real time stock price chart below.
What Is the Sarepta Therapeutics Inc Stock Price Today?
The Sarepta Therapeutics Inc stock price today is 16.88.
What Is the Stock Symbol for Sarepta Therapeutics Inc?
The stock symbol for Sarepta Therapeutics Inc is "SRPT."
What Stock Exchange Does Sarepta Therapeutics Inc Trade On?
Sarepta Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sarepta Therapeutics Inc a Good Stock to Buy?
Determining whether Sarepta Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SRPT quote. (ISIN: US8036071004)
What Is the Sarepta Therapeutics Inc Stock Price Today?
The Sarepta Therapeutics Inc stock price today is 16.88.
What Is the Stock Symbol for Sarepta Therapeutics Inc?
The stock symbol for Sarepta Therapeutics Inc is "SRPT."
What Stock Exchange Does Sarepta Therapeutics Inc Trade On?
Sarepta Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sarepta Therapeutics Inc a Good Stock to Buy?
Determining whether Sarepta Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SRPT quote. (ISIN: US8036071004)
16.88
-2.09(-11.02%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.41
17.84
52 wk Range
10.42
109.50
SRPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.4117.84
52 wk Range
10.42109.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SRPT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
21.43
Upside
+26.98%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Sarepta Therapeutics Inc Company Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics Inc SWOT Analysis
Gene Therapy Setbacks | Delve into Sarepta's challenges with Elevidys, including safety concerns and regulatory hurdles, impacting its market position and financial outlook |
Pipeline Potential | Explore Sarepta's diverse pipeline beyond DMD, including promising treatments for LGMD and other rare neuromuscular diseases |
Market Dynamics | Uncover Sarepta's competitive landscape, strategic partnerships, and potential threats from emerging therapies in the muscular dystrophy market |
Financial Trajectory | Analyst price targets range from $21 to $210, reflecting diverse views on Sarepta's future prospects amid current challenges and long-term growth potential |
Sarepta Therapeutics Inc Earnings Call Summary for Q4/2025
- Q4 2025 EPS of -$3.58 missed forecast of -$1.21, while revenue of $442.9M beat expectations by 16.64% on strong product demand.
- Full-year 2025 revenue reached $2.2B, up 16% YoY, driven by PMO franchise and ELEVIDYS gene therapy performance.
- Company ended year with $954M in cash and investments, generating $330M positive operating cash flow for 2025.
- Management projects positive cash flow and non-GAAP profitability in 2026, focusing on pipeline investments and ELEVIDYS expansion.
- Stock rose 0.32% to $18.90 in aftermarket trading despite EPS miss, as investors focused on revenue beat and improved outlook.
Last Updated: 02/26/2026, 07:18 AM
Read Full TranscriptCompare SRPT to Peers and Sector
Metrics to compare | SRPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.3x | 7.7x | −0.6x | |
PEG Ratio | 0.02 | 0.12 | 0.00 | |
Price/Book | 1.5x | 1.3x | 2.6x | |
Price / LTM Sales | 0.8x | 4.6x | 3.3x | |
Upside (Analyst Target) | 0.2% | 17.1% | 44.5% | |
Fair Value Upside | Unlock | −4.8% | 5.0% | Unlock |
Analyst Ratings
7 Buy
14 Hold
5 Sell
Ratings:
26 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 21.43
(+26.98% Upside)
Earnings
Latest Release
Feb 25, 2026
EPS / Forecast
-3.58 / -1.21
Revenue / Forecast
442.90M / 379.71M
People Also Watch
FAQ
What Is the Sarepta (SRPT) Stock Price Today?
The Sarepta stock price today is 16.88 USD.
What Stock Exchange Does Sarepta Trade On?
Sarepta is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Sarepta?
The stock symbol for Sarepta is "SRPT."
What Is the Sarepta Market Cap?
As of today, Sarepta market cap is 1.78B USD.
What Is Sarepta's Earnings Per Share (TTM)?
The Sarepta EPS (TTM) is -2.77.
When Is the Next Sarepta Earnings Date?
Sarepta will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is SRPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Sarepta Stock Split?
Sarepta has split 1 times.
How Many Employees Does Sarepta Have?
Sarepta has 1372 employees.
What is the current trading status of Sarepta (SRPT)?
As of Feb 26, 2026, Sarepta (SRPT) is trading at a price of 16.88 USD, with a previous close of 18.97 USD. The stock has fluctuated within a day range of 16.41 USD to 17.84 USD, while its 52-week range spans from 10.42 USD to 109.50 USD.
What Is Sarepta (SRPT) Price Target According to Analysts?
The average 12-month price target for Sarepta is 21.43 USD, with a high estimate of 45 USD and a low estimate of 5 USD. 7 analysts recommend buying the stock, while 5 suggest selling, leading to an overall rating of Neutral. The stock has an +26.98% Upside potential.
What Is the SRPT Premarket Price?
SRPT's last pre-market stock price is 17.75 USD. The pre-market share volume is 61,460.00, and the stock has decreased by -1.22, or -6.43%.
What Is the SRPT After Hours Price?
SRPT's last after hours stock price is 17.95 USD, the stock has decreased by -1.02, or -5.38%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.